相关实验视频

Updated: Jun 3, 2025

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

FT538,iPSC衍生的NK细胞,在与化疗相结合时增强AML细胞杀死

Amanda Eckstrom¹, Anudishi Tyagi¹, Sajid Mahmood²

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Journal of cellular and molecular medicine

|January 11, 2025

概括

工程诱导的多能干细胞衍生自然杀手 (iPSC-NK) 细胞显示出治疗急性髓性白血病 (AML) 的前景. 这些新型iPSC-NK细胞有效地杀死AML细胞,包括高风险和耐药类型,并在组合疗法中显示出潜力.

科学领域:

免疫学免疫学免疫学
细胞生物学细胞生物学
血液学血液学血液学

背景情况:

急性髓性白血病 (AML) 仍然是一个具有挑战性的血液恶性瘤,对高风险和耐药病例的治疗选择有限.
目前对AML的治疗标准在有效性和适用于广泛患者群体的限制.
基于自然杀手 (NK) 细胞的疗法为现有治疗提供了潜力,但在标准化和有效性方面仍然存在挑战.

研究的目的:

评估FT538诱导多能干细胞衍生自然杀手 (iPSC-NK) 细胞对急性髓性白血病 (AML) 的治疗潜力.
评估FT538 iPSC-NK细胞对AML细胞系和初级患者细胞的疗效,包括高风险和耐药亚型.
研究FT538 iPSC-NK细胞与标准AML化疗相结合的协同作用潜力.

主要方法:

使用工程 FT538 iPSC-NK 细胞,具有增强的功能:高亲和度 CD16,CD38 淘汰,以及 IL-15/IL-15 受体融合.
评估FT538 iPSC-NK细胞对AML细胞系和AML初级细胞的细胞毒性作用,使用效应器与点细胞的比率.
进行了流动细胞计量分析,以评估AML细胞死亡与cytarabine,venetoclax和gilteritinib结合使用,并评估FT538 iPSC-NK与cytarabine的活力.

主要成果:

FT538 iPSC-NK 细胞在AML细胞系和初级AML细胞中都表现出效应对细胞比率依赖的亡.
即使在高风险患者的AML细胞和对标准疗法的耐药性患者中也观察到有效性.
结合治疗与cytarabine,venetoclax或gilteritinib增强了由FT538 iPSC-NK细胞诱导的AML细胞死亡.
基塔拉宾治疗没有损害FT538 iPSC-NK细胞的活力,这表明它们是兼容的.

结论:

FT538 iPSC-NK细胞代表了AML的有希望的治疗策略,特别是在高风险和耐治疗人群中.
经过工程设计的iPSC-NK细胞通过增强的细胞毒性和改善的代谢适应性,表现出强大的抗白血病活性.
结合iPSC-NK细胞疗法与常规化疗,如cytarabine,保证进一步调查作为潜在的协同治疗方法对AML.

关键词:

在AML,AML就是AML.在NK细胞疗法中使用NK细胞疗法.通过NK细胞介导的亡.来自iPSC的NK细胞.免疫疗法免疫疗法

更多相关视频

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.